French Study Shows 22% of ALS Patients Use CBD for Treatment

According to representatives of the public organization NORML, about 22% of all French residents diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, regularly use CBD for self-treatment, despite existing restrictions on cannabis in the country. These findings were published in the French scientific journal Revue Neurologique, based on a patient survey.

The surveyed patients reported that cannabis significantly improves their physical well-being and energy levels, particularly by reducing pain, improving limb mobility, and positively affecting their overall mood.

“This type of survey was conducted for the first time in a country where cannabis is still strictly prohibited, and it clearly shows us that cannabis works well as a medicine for chronic diseases. It also demonstrates that many people use the plant as medicine despite potential legal issues,” NORML representatives concluded in their review of the study. “Moreover, the study confirms the need for further research into the effectiveness and safety of cannabis use in treating Lou Gehrig’s disease.”

Existing private studies also note that even small amounts of cannabis use can significantly slow the progression of this disease. Soon, this information may be confirmed by the results of clinical trials currently underway in Australia, which are expected to conclude by the end of this year.